NDA 020491 · Pfizer
Corvert
Ibutilide Fumarate · Injection
NovelLast checked: Nov 19, 2026Latest source record: Jun 9, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Dec 28, 1995
Approved uses
2
Original approval plus efficacy supplements
Registered trials
8
0 Phase 3, 0 recruiting
FAERS reports
31
25 serious, 4 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
LIFE-THREATENING ARRHYTHMIAS—APPROPRIATE TREATMENT ENVIRONMENT CORVERT can cause potentially fatal arrhythmias, particularly sustained polymorphic ventricular tachycardia, usually in association with QT prolongation (torsades de pointes), but sometimes without documented QT prolongation. In registration studies, these arrhythmias, which require cardioversion, occurred in 1.7% of treated patients during, or within a number of hours of, use of CORVERT. These arrhythmias can be reversed if treated promptly (see WARNINGS, Proarrhythmia ). It is essential that CORVERT be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia. Patients with atrial fibrillation of more than 2 to 3 days' duration must be adequately anticoagulated, generally for at least 2...
What it is approved for
From the label in effect Jan 25, 2024.
INDICATIONS AND USAGE CORVERT Injection is indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm. Patients with atrial arrhythmias of longer duration are less likely to respond to CORVERT. The effectiveness of ibutilide has not been determined in patients with arrhythmias of more than 90 days in duration.
Mechanism: Mechanism of Action: CORVERT Injection prolongs action potential duration in isolated adult cardiac myocytes and increases both atrial and ventricular refractoriness in vivo , ie, class III electrophysiologic effects. Voltage clamp studies indicate that CORVERT, at nanomolar concentrations, delays repolarization by activation of a slow, inward current (predominantly sodium), rather than by blocking outward potassium currents, which is the mechanism by which most other class III antiarrhythmics act. These effects lead to prolongation of atrial and ventricular action potential duration and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 13, 1999 Supplement 1 · Efficacy ReviewLetterLabel
- Dec 28, 1995 Original approval · Type 1 - New Molecular Entity Review
1 products under this application
- CORVERT · IBUTILIDE FUMARATE 0.1MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Ibutilide" as an intervention, any sponsor and status, largest first.
- Modified Ablation Guided by Ibutilide Use in Chronic Atrial FibrillationPivotal-lookingCompleted
Vivek ReddyAcademic, hospital or other
NCT01014741 · 200 participants · Start Oct 2009 · Primary completion Jan 2015
Drug: Ibutilide; Placebo · For: Persistent Atrial Fibrillation
Sites: Sacramento, California; Boston, Massachusetts; New York, New York · 7 sites in all
- Vernakalant Versus Ibutilide In Recent-Onset Atrial FibrillationPivotal-lookingCompleted
Medical University of ViennaAcademic, hospital or other
NCT01447862 · 101 participants · Start Oct 2011 · Primary completion May 2015
Drug: Brinavess (Vernakalant); Corvert (Ibutilide) · For: Atrial Fibrillation
Sites: Vienna, Austria
Indiana UniversityAcademic, hospital or other
NCT04675788 · 73 participants · Start Sep 2, 2021 · Primary completion Apr 16, 2025
Drug: Progesterone; Ibutilide and 2 more · For: Long QT Syndrome; Abnormalities, Drug-Induced
Sites: Indianapolis, Indiana · 3 sites in all
- Ibutilide Administration During Pulmonary Vein AblationStatus unknown
Ball Memorial HospitalAcademic, hospital or other
NCT00589992 · 50 participants (planned) · Start Oct 2007 · Primary completion Dec 2015
Drug: Ibutilide fumarate · For: Atrial Fibrillation; Pulmonary Vein Ablation
Sites: Muncie, Indiana
Indiana UniversityAcademic, hospital or other
NCT03834883 · 27 participants · Start Mar 26, 2019 · Primary completion May 21, 2024
Drug: Progesterone; Ibutilide · For: Long QT Syndrome; Abnormalities, Drug-Induced
Sites: Indianapolis, Indiana
Indiana UniversityAcademic, hospital or other
NCT01929083 · 19 participants · Start Apr 2013 · Primary completion Jun 2014
Drug: Progesterone; Placebo and 1 more · For: Prolonged QT Interval in EKG and Sudden Death
Sites: Indianapolis, Indiana · 2 sites in all
Indiana UniversityAcademic, hospital or other
NCT02513940 · 14 participants · Start May 2016 · Primary completion Oct 19, 2017
Drug: Testosterone; Progesterone and 2 more · For: Long QT Syndrome
Sites: Indianapolis, Indiana
Vivek ReddyAcademic, hospital or other
NCT03370536 · 1 participants · Start Nov 1, 2017 · Primary completion Jul 18, 2018
Drug: Ibutilide · For: Atrial Fibrillation; Persistent Atrial Fibrillation
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- torsade de pointes6
- electrocardiogram qt prolonged5
- ventricular tachycardia5
- atrial fibrillation4
- asthenia2
- cardiac arrest2
- drug interaction2
- dyspnoea2
- escherichia infection2
- hypotension2
- neutropenia2
- product dose omission issue2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 5 |
| 2013 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Short QT syndrome: pharmacological treatment.
Gaita F, Giustetto C, Bianchi F, et al. · J Am Coll Cardiol 2004 · Clinical Trial
- External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis.
Kukendrarajah K, Ahmad M, Carrington M, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Intravenous Flecainide for Emergency Department Management of Acute Atrial Fibrillation.
Markey GC, Salter N, Ryan J · J Emerg Med 2018 · Meta-Analysis, Systematic Review
- Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation.
Korantzopoulos P, Kolettis TM, Papathanasiou A, et al. · Heart 2006 · Randomized Controlled Trial
- Autonomic tone attenuates drug-induced QT prolongation.
Smith AH, Norris KJ, Roden DM, et al. · J Cardiovasc Electrophysiol 2007 · Clinical Trial, Research Support, N.I.H., Extramural
- Association of hypokalemia with an increased risk for medically treated arrhythmias.
Phillips CT, Wang J, Celi LA, et al. · PLoS One 2019 · Clinical Trial, Multicenter Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.